-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
finishinghaon
According to the public account "Huashan Infection", the first clinical study of the anti-new coronavirus small molecule oral drug VV116 in Omicron infected subjects in China was releas.
The research data suggest that the time of negative nucleic acid conversion of Omicron-infected patients who used VV116 within 5 days of the first nucleic acid test was 56 days, which was less than 113 days for the control gro.
▲The picture comes from the public account of "Huashan Infection"
It is reported that the relevant results were published in the journal Emerging Microbes & Infections on May 1 Professor Shen Yinzhong of Shanghai Public Health Clinical Center is the first author of the article, and Professor Zhang Wenhong and Professor Fan Xiaohong of Shanghai Public Health Clinical Center are the co-corresponding authors of the artic.
▲The picture comes from the public account of "Huashan Infection"
Specifically, in symptomatic patients, administration of VV116 within the medication time range of this study (2-10 days after the first nucleic acid positive) can shorten the time of the patient's nucleic acid conversion to negati.
In terms of drug safety, no serious adverse reactions were observed in patients using VV11 The study included a limited sample size, and none of the subjects developed severe or critical illne.
This is the first peer-reviewed report on the clinical study results of "domestic" anti-new coronavirus drugs on people infected with Omicr.
It should be noted that, as an open-label, prospective cohort study, the sample size included in this study was limited, and none of the subjects developed severe or critical illne.
At present, there are a number of phase II-III studies of antiviral drugs underway or about to be carried out in Chi.
This is the first peer-reviewed report on the clinical study results of "domestic" anti-new coronavirus drugs on people infected with Omicr.
references:
SHEN YZ, AI JW, Lin N, .
XIE Y, YIN W, ZHANG Y, .
QIAN HJ, WANG Y, ZHANG MQ, .
The article is reproduced from: Huashan Infection "The first clinical study of the anti-new coronavirus small molecule oral drug VV116 in Chinese Omicron infected subjects is released"
